← Back to Clinical Trials
Recruiting NCT06930183

NCT06930183 Awake Thoracic Epidural Anesthesia Versus General Anesthesia in Thoracotomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06930183
Status Recruiting
Phase
Sponsor Cairo University
Condition Awake
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-04-16
Primary Completion 2025-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Awake thoracic epidural anesthesiaGeneral anesthesia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-04-16 with a primary completion date of 2025-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare awake thoracic epidural anesthesia and general anesthesia in thoracotomy.

Eligibility Criteria

Inclusion Criteria: * Age from 18 to 75 years old. * Both genders. * American Society of Anesthesiologists (ASA) physical status classification II or III. * Scheduled for thoracotomy. Exclusion Criteria: * Difficult airway management, * Hemodynamically unstable patients, obesity (body mass index \>30). * Absolute contraindication to thoracic epidural anesthesia such as (patient refusal, allergy to local anesthetics, coagulopathy, active neurologic disorders, skin infection at insertion site, uncooperative patients, uncontrolled cough, and unfavorable anatomy for thoracic epidural). * Neurological disorders: risk of seizure, unable to cooperate, intracranial mass or brain edema, extensive pleural adhesions or previous pulmonary resections, hypoxemia (PaO2 \<60) or hypercarbia (PaCO2 \>50) * Poor cardiac function (ejection fraction less than 50%). * Patients with bad pulmonary function tests.

Contact & Investigator

Central Contact

Mohamed E Abdel Fattah, MD

✉ mohamed-elsaid@cu.edu.eg

📞 00201284475792

Frequently Asked Questions

Who can join the NCT06930183 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Awake. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06930183 currently recruiting?

Yes, NCT06930183 is actively recruiting participants. Contact the research team at mohamed-elsaid@cu.edu.eg for enrollment information.

Where is the NCT06930183 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06930183 clinical trial?

NCT06930183 is sponsored by Cairo University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology